Vascular Angiotensin Type-2 Receptor in Normal and Hypertensive Pregnancy
正常妊娠和高血压妊娠中的血管紧张素 2 型受体
基本信息
- 批准号:7640314
- 负责人:
- 金额:$ 8.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-08 至 2011-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAngiotensin IIAngiotensin II Type 1 Receptor BlockersAngiotensinsAnimalsAortic SegmentApplications GrantsBlood PressureBlood VesselsBradykininBradykinin ReceptorCyclic AMPCyclic GMPCyclooxygenase InhibitorsDataEndothelial CellsEndotheliumEpoprostenolFunctional disorderHypertensionImmunohistochemistryIn VitroKidneyMeasurementMeasuresMediatingMembrane PotentialsMesenteric ArteriesModelingMolecularNitratesNitritesPathogenesisPathway interactionsPerfusionPhenylephrinePilot ProjectsPlayPotassium ChannelPre-EclampsiaPregnancyProductionProtein IsoformsRadiolabeledRattusReceptor, Angiotensin, Type 1RelaxationRenin-Angiotensin SystemReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSprague-Dawley RatsSystemTestingTissuesType 2 Angiotensin II ReceptorUnited States National Institutes of HealthUp-RegulationVasodilationVasodilator AgentsWestern Blottingchannel blockershemodynamicsin vivopregnancy hypertensionpressurepublic health relevanceradiotracerreceptorreceptor bindingreceptor-mediated signalingrenal arteryresearch studyresponsevasoconstriction
项目摘要
DESCRIPTION (provided by applicant): Upregulation of the renin-angiotensin system and increased vasoconstrictive response to angiotensin II (AngII) are observed during hypertension in pregnancy (HTN-Preg) and preeclampsia. Although the renin- angiotensin system is upregulated during normal pregnancy (Norm-Preg), reduction in blood pressure (BP) and blunted vascular contraction to AngII are often observed, and the vascular mechanisms involved are unclear. AngII activates angiotensin type 1 receptor (AT1R) to induce vasoconstriction, and angiotensin type 2 receptor (AT2R) to induce the release of vasodilator substances and promote vascular relaxation. The objective of this proposal is to test the hypothesis that AT2R-mediated signaling is an important regulator of vascular function and BP during pregnancy. During Norm-Preg, upregulation of vascular AT2R leads to enhanced vascular relaxation, blunting of vasoconstriction, and reduction in BP. Decreased expression/activity of AT2R-mediated signaling plays a role in the endothelial cell dysfunction and vasoconstriction associated with HTN-Preg, and consequently, increasing the activity of the AT2R system promotes vasodilation and decreases BP in HTN-Preg. Studies will be performed on virgin, Norm-Preg Sprague-Dawley rats and a rat model of HTN-Preg produced by reduction in uterine perfusion pressure (RUPP) during late pregnancy. Ex vivo and molecular studies will be performed on isolated renal and mesenteric arteries and pressurized microvessels. Aim 1 will determine whether the decreased BP and increased vasodilation during Norm-Preg reflects upregulation of vascular AT2R and postreceptor vascular relaxation pathways. Vascular contraction/relaxation to AngII and phenylephrine will be measured in the absence and presence of AT2R agonists and AT1R antagonists. Vascular AT2R will be quantified using RT-PCR, western blot analysis, and radiolabeled AT receptor binding studies, and localized using immunohistochemistry. Expression of vascular NOS and COX, and the AT2R-induced bradykinin release, nitrite/nitrate and PGI2 production, and membrane potential will be measured. Aim 2 will determine whether decreased expression/activity of AT2R-mediated signaling plays a role in the endothelial cell dysfunction and enhanced vasoconstriction associated with HTN-Preg. Experiments will test whether AT2R blockade by chronically infusing AT2R antagonist in Norm-Preg rats results in decreased vascular relaxation, and increased vasoconstriction and BP. We will also test whether AT2R-mediated signaling and vascular relaxation pathways are downregulated in RUPP rat model of HTN-Preg. Also, we will test whether enhancing the activity of the AT2R system promotes vasodilation and reduces BP in HTN-Preg. These studies should help to define better the role of vascular AT2R in enhancing vascular relaxation and reducing BP during Norm-Preg. The results will also provide a better understanding of the changes in the vascular AT2R system in the pathogenesis of HTN-Preg and preeclampsia.
PUBLIC HEALTH RELEVANCE: Although the role of angiotensin Type 1 receptor (AT1R) in vascular contraction is well-characterized, the role of angiotensin Type 2 receptor (AT2R) in vascular relaxation, particularly during pregnancy, is less clear. The objective of this grant proposal is to test the hypothesis that AT2R-mediated signaling is an important regulator of vascular function and BP during normal pregnancy. Decreased expression/activity of AT2R- mediated signaling pathways plays a role in the endothelial cell dysfunction and vasoconstriction associated with hypertension in pregnancy, and consequently, increasing the activity of the AT2R system promotes vasodilation and decreases BP in hypertension in pregnancy and preeclampsia.
描述(由申请人提供):在妊娠期高血压(HTN-Preg)和先兆子痫期间观察到肾素-血管紧张素系统的上调和对血管紧张素II(AngII)的血管收缩反应增加。尽管肾素-血管紧张素系统在正常妊娠期间上调(Norm-Preg),但常可观察到血压降低和血管对Angii的钝性收缩,其中涉及的血管机制尚不清楚。血管紧张素Ⅱ激活血管紧张素1型受体(AT1R)诱导血管收缩,激活血管紧张素2型受体(AT2R)诱导血管扩张物质释放,促进血管松弛。这一建议的目的是验证AT2R介导的信号是怀孕期间血管功能和血压的重要调节因素的假设。在Norm-Preg期间,血管AT2R的上调导致血管松弛增强,血管收缩减弱,血压降低。AT2R介导的信号表达/活性降低在HTN-Preg相关的内皮细胞功能障碍和血管收缩中起作用,因此,AT2R系统的活性增加促进了HTN-Preg的血管扩张和血压下降。研究将在处女、Norm-Preg Spraogue-Dawley大鼠和妊娠晚期降低子宫灌流压力(RUPP)产生的HTN-Preg大鼠模型上进行。体外和分子研究将在分离的肾动脉和肠系膜动脉以及加压的微血管上进行。目的1确定Norm-Preg过程中血压降低和血管扩张增加是否反映了血管AT2R和受体后血管松弛通路的上调。血管对血管紧张素Ⅱ和苯肾上腺素的收缩/松弛将在AT2R激动剂和AT1R拮抗剂的存在和不存在的情况下进行测量。血管AT2R将通过RT-PCR、Western印迹分析和放射性标记的AT受体结合研究进行定量,并使用免疫组织化学进行定位。测定血管一氧化氮合酶和环氧合酶的表达,AT2R诱导的缓激肽释放,亚硝酸盐/硝酸盐和前列腺素I2的产生,以及膜电位。目的2确定AT2R介导的信号通路表达/活性降低是否在HTN-Preg相关的内皮细胞功能障碍和血管收缩增强中起作用。实验将测试在Norm-Preg大鼠中长期注入AT2R拮抗剂阻断AT2R是否会导致血管松弛减少,血管收缩和血压增加。我们还将测试AT2R介导的信号和血管松弛通路在HTN-Preg的RUPP大鼠模型中是否下调。此外,我们还将测试增强AT2R系统的活性是否会促进HTN-Preg的血管扩张和降低血压。这些研究应该有助于更好地确定血管AT2R在Norm-Preg期间增强血管松弛和降低血压方面的作用。这一结果也将有助于更好地了解血管AT2R系统在HTN-Preg和子痫前期发病机制中的变化。
公共卫生相关性:尽管血管紧张素1型受体(AT1R)在血管收缩中的作用已被很好地描述,但血管紧张素2型受体(AT2R)在血管松弛中的作用尚不清楚,尤其是在妊娠期间。这项拨款提案的目的是验证AT2R介导的信号是正常妊娠期间血管功能和血压的重要调节因素的假设。AT2R介导的信号通路的表达/活性降低在妊娠高血压综合征相关的内皮细胞功能障碍和血管收缩中起作用,因此,AT2R系统的活性增加促进了妊娠高血压综合征和先兆子痫患者的血管扩张和血压下降。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Raouf A Khalil其他文献
Raouf A Khalil的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Raouf A Khalil', 18)}}的其他基金
Mechano-Sensitive Hypoxia-Inducible Factor-MMP Pathway in Venous Insufficiency
静脉功能不全中的机械敏感性缺氧诱导因子-MMP 通路
- 批准号:
8609058 - 财政年份:2013
- 资助金额:
$ 8.57万 - 项目类别:
Mechano-Sensitive Hypoxia-Inducible Factor-MMP Pathway in Venous Insufficiency
静脉功能不全中的机械敏感性缺氧诱导因子-MMP 通路
- 批准号:
8444239 - 财政年份:2013
- 资助金额:
$ 8.57万 - 项目类别:
Role of Endothelin B Receptor in Vascular Protection in Females
内皮素B受体在女性血管保护中的作用
- 批准号:
8123327 - 财政年份:2010
- 资助金额:
$ 8.57万 - 项目类别:
Role of Endothelin B Receptor in Vascular Protection in Females
内皮素B受体在女性血管保护中的作用
- 批准号:
7990293 - 财政年份:2010
- 资助金额:
$ 8.57万 - 项目类别:
Vascular Mechanisms in Pregnancy-Induced Hypertension
妊娠高血压综合征的血管机制
- 批准号:
7822236 - 财政年份:2009
- 资助金额:
$ 8.57万 - 项目类别:
Vascular Angiotensin Type-2 Receptor in Normal and Hypertensive Pregnancy
正常妊娠和高血压妊娠中的血管紧张素 2 型受体
- 批准号:
7835652 - 财政年份:2009
- 资助金额:
$ 8.57万 - 项目类别:
Vascular Protective Role of Endothelin B Receptors
内皮素 B 受体的血管保护作用
- 批准号:
7125509 - 财政年份:2003
- 资助金额:
$ 8.57万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 8.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 8.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 8.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)